Objective:To explore the effects of Baduanjin combined with staged rehabilitation exercise in patients after percutaneous transforaminal endoscopic discectomy (PTED) .Methods:From May 2018 to May 2019, convenience sampling was used to select 141 patients after PTED admitted to Zhoushan Hospital of Traditional Chinese Medicine in Zhejiang Province as the research objects. According to the random number table, patients were divided into Baduanjin group, staged rehabilitation exercise group and combined group, with 47 cases in each group. Baduanjin group implemented the Baduanjin intervention on the basis of conventional nursing, staged rehabilitation exercise group was given the rehabilitation exercise intervention on the basis of conventional nursing, and combined group carried out the Baduanjin combined with staged rehabilitation exercise intervention on the basis of conventional nursing. The Japanese Orthopaedic Association Scores (JOA) , Oswestry Disability Index (ODI) and the Rehabilitation Exercise Compliance Scale were used to assess patients' rehabilitation exercise status. During the course of the study, five subjects withdrew from the study, including one in combined group, three in Baduanjin group, and one in staged rehabilitation exercise group.Results:A total of 90 days after the intervention, the JOA score of combined group was higher than that of Baduanjin group and staged rehabilitation exercise group, and the ODI score was lower than that of Baduanjin group and staged rehabilitation exercise group, the differences were statistically significant ( P<0.05) . The total compliance rate of rehabilitation exercise in combined group was higher than that in Baduanjin group and staged rehabilitation exercise group, and the difference was statistically significant ( P<0.05) . Conclusions:The scientific and reasonable intervention of Baduanjin combined with staged rehabilitation exercise for lumbar disc herniation patients after PTED can not only effectively increase the patient's comfort and compliance with rehabilitation exercises, but also effectively improve patient dysfunction and low back pain. It has high clinical application and promotion value.

A 51-year-old male patient with hyperlipidemia, uremia, uremic cardiomyopathy,hypertension, osteoporosis and type 2 diabetes received atorvastatin calcium 20 mg/d, olmesartan 20 mg/d,nifedipine 30 mg/d, isosorbide 5-mononitrate 40 mg/d, calcitriol 0.5 μg/d, calcium acetate 0.6 g/d.In addition, the patient received hypodermic injection of insulin according to blood sugar level, and maintained peritoneal dialysis.The patient stopped using atorvastatin and switched to bezafibrate dispersible tablets 0.2 gthree time daily because of his high levels of total cholesterol (7.0 mmol/L) and triacylglycerol (9.9 mmol/L).On day 4 of changing the prescription, the patient complained of whole body pain.On day 6 of changing the prescription, the patient became anxious, irritable, and had darkened peritoneal dialysis fluid.Laboratory test showed the following values: white blood cell count (WBC) 33.0 × 109/L, neutrophil 0.95, creatine kinase (CK) ＞ 10 000 U/L, myoglobin 2 876 μg/L, alanine aminotransferase (ALT) 460 U/L, urea 20.9 mmol/L, and creatinine (Cr) 1 294 μmol/L on day 7 of changing medical prescription.The patient was diagnosed as rhabdomyolysis due to bezafibrate.Bezafibrate was withdrawn on the same day.He received the symptonatic treatments including liver and kidney protcction, nourishing myocardium, and vein-vein hemodialysis besides continuing to take the other drugs mentioned above.On day 7 of stopping bezafibrate the patient's mental symptoms improved.Laboratory test showed the following values: WBC 16.0 × 109/L, neutrophil 0.81, CK 154 U/L, myoglobin 288 μg/L, ALT 21 U/L, urea 12.0 mmol/L,and Cr 564 μmol/L on day 16 of stopping bezafibrate.The patient did not complain of pain, the symptoms of anxiety and irritability did not appear until the day 60 of drug withdrawal.

A 51-year-old male patient with hyperlipidemia, uremia, uremic cardiomyopathy,hypertension, osteoporosis and type 2 diabetes received atorvastatin calcium 20 mg/d, olmesartan 20 mg/d,nifedipine 30 mg/d, isosorbide 5-mononitrate 40 mg/d, calcitriol 0.5 μg/d, calcium acetate 0.6 g/d.In addition, the patient received hypodermic injection of insulin according to blood sugar level, and maintained peritoneal dialysis.The patient stopped using atorvastatin and switched to bezafibrate dispersible tablets 0.2 gthree time daily because of his high levels of total cholesterol (7.0 mmol/L) and triacylglycerol (9.9 mmol/L).On day 4 of changing the prescription, the patient complained of whole body pain.On day 6 of changing the prescription, the patient became anxious, irritable, and had darkened peritoneal dialysis fluid.Laboratory test showed the following values: white blood cell count (WBC) 33.0 × 109/L, neutrophil 0.95, creatine kinase (CK) ＞ 10 000 U/L, myoglobin 2 876 μg/L, alanine aminotransferase (ALT) 460 U/L, urea 20.9 mmol/L, and creatinine (Cr) 1 294 μmol/L on day 7 of changing medical prescription.The patient was diagnosed as rhabdomyolysis due to bezafibrate.Bezafibrate was withdrawn on the same day.He received the symptonatic treatments including liver and kidney protcction, nourishing myocardium, and vein-vein hemodialysis besides continuing to take the other drugs mentioned above.On day 7 of stopping bezafibrate the patient's mental symptoms improved.Laboratory test showed the following values: WBC 16.0 × 109/L, neutrophil 0.81, CK 154 U/L, myoglobin 288 μg/L, ALT 21 U/L, urea 12.0 mmol/L,and Cr 564 μmol/L on day 16 of stopping bezafibrate.The patient did not complain of pain, the symptoms of anxiety and irritability did not appear until the day 60 of drug withdrawal.